What does Pharmacie BAECKEN do?

Pharmacie BAECKEN is a pharmacy in Nandrin. Public Limited, started on 21 December 1989, 1 establishment.

What is the address of Pharmacie BAECKEN?

The registered office of Pharmacie BAECKEN is located at Route du Condroz 207, 4550 Nandrin.

Is Pharmacie BAECKEN still active?

Yes. According to the CBE (29 October 2026) Pharmacie BAECKEN is active, legal situation “Normale toestand”, started on 21 December 1989.

Is Pharmacie BAECKEN registered on Peppol?

Yes, Pharmacie BAECKEN is registered on the Peppol network with ID 0208:0439221839.

What is the enterprise number of Pharmacie BAECKEN?

The enterprise number of Pharmacie BAECKEN is BE0439221839.

When was Pharmacie BAECKEN founded?

Pharmacie BAECKEN was founded on 21 December 1989.

Who are the directors of Pharmacie BAECKEN?

According to the 2025 annual accounts, the directors of Pharmacie BAECKEN are: François Van Sull, Pascal Crits, Pierre Wagner, Corinne Baecken.

Is Pharmacie BAECKEN a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 21 December 1989; 5 annual accounts filed, latest fiscal year 2025; 4 directors known from the annual account.

How much profit did Pharmacie BAECKEN make in 2025?

Pharmacie BAECKEN posted a profit after taxes of € 157,338 in financial year 2025.

What is the revenue of Pharmacie BAECKEN?

As a small company, Pharmacie BAECKEN is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 379,526.

How much does an employee at Pharmacie BAECKEN earn?

The average wage cost per full-time employee at Pharmacie BAECKEN was € 44,200 in 2025: staff costs of € 75,126 for 1.7 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does Pharmacie BAECKEN have?

According to the 2025 annual accounts, Pharmacie BAECKEN has 1.7 full-time equivalents (FTE).

Pharmacie BAECKEN (Public Limited) - Nandrin

Dossier Pharmacie BAECKEN, printed on 29 October 2026 from databakkes.be/en/0439221839/pharmacie-baecken. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

Pharmacie BAECKEN from Nandrin, company number BE0439221839, closed financial year 2025 with a result of € 157,338 after tax. For that financial year Pharmacie BAECKEN recorded a gross margin of € 379,526 and equity of € 717,056. Compared with financial year 2024, the result moved from € 12,918 to € 157,338. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 22, 2026.

What it is worth Growing

€ 717,056

▲ 28% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 157,338

▲ € 144,420 vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 175,114

▲ 60% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 655,556.

People and assets in 2025

Full-time equivalents

1.7

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 75,126

▼ 24% vs 2024

€ 44,200 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 1,310

▼ 94% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 9 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 392,588

▼ 10% vs 2024

€ 43,527 is repaid this year. At this pace the long-term loan is gone in ≈ 9 years.

Owed to suppliers

€ 1,653

▼ 97% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 22,823

▼ 18% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 242,520 Gross margin 2022: € 242,520 First fiscal year in the series	€ 238,913 Gross margin 2023: € 238,913 ▼ 1% vs 2022 (€ 242,520) Unfavourable step	€ 216,384 Gross margin 2024: € 216,384 ▼ 9% vs 2023 (€ 238,913) Unfavourable step	€ 379,526 Gross margin 2025: € 379,526 ▲ 75% vs 2024 (€ 216,384) Favourable step	▲ 75%
Profit after taxes	€ 19,649 Profit after taxes 2022: € 19,649 First fiscal year in the series	€ 12,603 Profit after taxes 2023: € 12,603 ▼ 36% vs 2022 (€ 19,649) Unfavourable step	€ 12,918 Profit after taxes 2024: € 12,918 ▲ 2% vs 2023 (€ 12,603) Favourable step	€ 157,338 Profit after taxes 2025: € 157,338 ▲ € 144,420 vs 2024 (€ 12,918) Favourable step	▲ € 144,420
Equity	€ 534,197 Equity 2022: € 534,197 First fiscal year in the series	€ 546,800 Equity 2023: € 546,800 ▲ 2% vs 2022 (€ 534,197) Favourable step	€ 559,718 Equity 2024: € 559,718 ▲ 2% vs 2023 (€ 546,800) Favourable step	€ 717,056 Equity 2025: € 717,056 ▲ 28% vs 2024 (€ 559,718) Favourable step	▲ 28%
Total debts	€ 969,204 Total debts 2022: € 969,204 First fiscal year in the series	€ 891,201 Total debts 2023: € 891,201 ▼ 8% vs 2022 (€ 969,204) Favourable step	€ 830,892 Total debts 2024: € 830,892 ▼ 7% vs 2023 (€ 891,201) Favourable step	€ 418,028 Total debts 2025: € 418,028 ▼ 50% vs 2024 (€ 830,892) Favourable step	▼ 50%
Cash	€ 209,195 Cash 2022: € 209,195 First fiscal year in the series	€ 88,703 Cash 2023: € 88,703 ▼ 58% vs 2022 (€ 209,195) Unfavourable step	€ 109,625 Cash 2024: € 109,625 ▲ 24% vs 2023 (€ 88,703) Favourable step	€ 175,114 Cash 2025: € 175,114 ▲ 60% vs 2024 (€ 109,625) Favourable step	▲ 60%
Land & buildings	€ 677,422 Land & buildings 2022: € 677,422 First fiscal year in the series	€ 676,650 Land & buildings 2023: € 676,650 Unchanged (€ 677,422) Unchanged	€ 639,173 Land & buildings 2024: € 639,173 ▼ 6% vs 2023 (€ 676,650) Unchanged	€ 535,621 Land & buildings 2025: € 535,621 ▼ 16% vs 2024 (€ 639,173) Unchanged	▼ 16%
Retained profit	€ 472,697 Retained profit 2022: € 472,697 First fiscal year in the series	€ 485,300 Retained profit 2023: € 485,300 ▲ 3% vs 2022 (€ 472,697) Favourable step	€ 498,218 Retained profit 2024: € 498,218 ▲ 3% vs 2023 (€ 485,300) Favourable step	€ 655,556 Retained profit 2025: € 655,556 ▲ 32% vs 2024 (€ 498,218) Favourable step	▲ 32%
Bank debt	€ 518,467 Bank debt 2022: € 518,467 First fiscal year in the series	€ 477,277 Bank debt 2023: € 477,277 ▼ 8% vs 2022 (€ 518,467) Favourable step	€ 435,322 Bank debt 2024: € 435,322 ▼ 9% vs 2023 (€ 477,277) Favourable step	€ 392,588 Bank debt 2025: € 392,588 ▼ 10% vs 2024 (€ 435,322) Favourable step	▼ 10%
Balance sheet total	€ 1,503,401 Balance sheet total 2022: € 1,503,401 First fiscal year in the series	€ 1,438,001 Balance sheet total 2023: € 1,438,001 ▼ 4% vs 2022 (€ 1,503,401) Unchanged	€ 1,390,610 Balance sheet total 2024: € 1,390,610 ▼ 3% vs 2023 (€ 1,438,001) Unchanged	€ 1,183,375 Balance sheet total 2025: € 1,183,375 ▼ 15% vs 2024 (€ 1,390,610) Unchanged	▼ 15%
Employees (FTE)	2.4 Employees (FTE) 2022: 2.4 First fiscal year in the series	2.1 Employees (FTE) 2023: 2.1 ▼ 0.3 vs 2022 (2.4) Unchanged	1.7 Employees (FTE) 2024: 1.7 ▼ 0.4 vs 2023 (2.1) Unchanged	1.7 Employees (FTE) 2025: 1.7 Unchanged (1.7) Unchanged

Key figures of Pharmacie BAECKEN, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Pharmacie BAECKEN?

What happened at Pharmacie BAECKEN in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2031 François Van Sull stepped down as director. NBB
2031 Pierre Wagner stepped down as director. NBB
Jul 22, 2026 New annual accounts for financial year 2025: profit of € 157,338 (▲ € 144,420 vs 2024). Source: NBB ↗
2025 François Van Sull became a director. NBB
2025 Pascal Crits stepped down as director. NBB
2025 Pierre Wagner became a director. NBB
2025 Corinne Baecken stepped down as director. NBB
2020 Pascal Crits became a director. NBB

In short

From € 19,649 profit in 2022 to € 157,338 profit in 2025.

Paid € 20,756 in corporate taxes since 2022.

Best year ever: 2025, with € 157,338 profit.

On average € 223,300 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

P4INVEST 100%

The stake of P4INVEST comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

Pharmacie BAECKEN

The shares are held by P4INVEST (100%).

Directors

According to the 2025 annual accounts

François Van Sull

Director

Also active at: PHARMACIE PIERRE WAGNER, PHARMACIE D'HELECINE, SOPHARMA MANAGEMENT, FVS Management, Pharma Construct, PHARMACIE BODEN

since 2025 · until 2031

Pascal Crits

Director

since 2020 · until 2025

Pierre Wagner

Director

Also active at: P4INVEST, P4HOLDING, PHARMACIE BODEN

since 2025 · until 2031

Corinne Baecken

Managing director

since 2020 · until 2025

Shareholders

P4INVEST

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Route du Condroz 207

4550 Nandrin

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0439.221.839

VAT number

BE 0439.221.839

Registered office

Route du Condroz 207, 4550 Nandrin

Names & denominations

Pharmacie BAECKEN

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

21 December 1989

Peppol

Active · Active since 9 Jan 2026

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

View on CBE Public ↗ Annual accounts (NBB) ↗

Pharmacie BAECKEN

Financials

What happened to Pharmacie BAECKEN?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Details

Frequently asked questions